Mckinley Capital Management LLC Delaware Has $577,000 Holdings in Kite Pharma, Inc. (KITE)

Mckinley Capital Management LLC Delaware trimmed its holdings in shares of Kite Pharma, Inc. (NASDAQ:KITE) by 29.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,206 shares of the biopharmaceutical company’s stock after selling 1,315 shares during the period. Mckinley Capital Management LLC Delaware’s holdings in Kite Pharma were worth $577,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of KITE. Dimensional Fund Advisors LP purchased a new stake in Kite Pharma during the first quarter valued at about $5,198,000. Bank of America Corp DE boosted its position in Kite Pharma by 119.6% during the first quarter. Bank of America Corp DE now owns 46,150 shares of the biopharmaceutical company’s stock valued at $3,622,000 after buying an additional 25,135 shares during the period. Bank of Montreal Can raised its stake in shares of Kite Pharma by 17.0% during the second quarter. Bank of Montreal Can now owns 8,898 shares of the biopharmaceutical company’s stock valued at $923,000 after acquiring an additional 1,293 shares during the last quarter. Aperio Group LLC raised its stake in shares of Kite Pharma by 35.9% during the second quarter. Aperio Group LLC now owns 6,279 shares of the biopharmaceutical company’s stock valued at $651,000 after acquiring an additional 1,660 shares during the last quarter. Finally, Shell Asset Management Co. bought a new position in shares of Kite Pharma during the second quarter valued at about $633,000. Institutional investors and hedge funds own 87.72% of the company’s stock.

In related news, CFO Paul L. Jenkinson sold 948 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total value of $170,317.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Cynthia M. Butitta sold 4,228 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $179.66, for a total transaction of $759,602.48. Following the completion of the transaction, the chief operating officer now directly owns 125,795 shares of the company’s stock, valued at $22,600,329.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,936 shares of company stock valued at $8,791,842. 14.00% of the stock is owned by insiders.

Several brokerages have recently commented on KITE. SunTrust Banks downgraded shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Wedbush raised shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. Canaccord Genuity downgraded shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Guggenheim downgraded shares of Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 price objective for the company. in a research note on Monday, August 28th. Finally, BTIG Research downgraded shares of Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Thirteen research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $94.68.

Kite Pharma, Inc. (NASDAQ KITE) opened at $179.79 on Friday. Kite Pharma, Inc. has a one year low of $39.82 and a one year high of $179.95.

TRADEMARK VIOLATION WARNING: “Mckinley Capital Management LLC Delaware Has $577,000 Holdings in Kite Pharma, Inc. (KITE)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/03/mckinley-capital-management-llc-delaware-has-577000-holdings-in-kite-pharma-inc-kite.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma, Inc. (NASDAQ:KITE).

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

What are top analysts saying about Kite Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kite Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit